4 recruiting, 1 unknown. 5 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 4, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Sarcoma of Bone: new trials by email Literature Review of Sarcoma of Bone trials Research Report on Sarcoma of Bone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas CD146/HER2 CAR-T cells - Sarcoma, Sarcoma, Kaposi | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2025-05-29 | 2025-07-15 |
| XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma Biospecimen Collection, Computed Tomography, Echocardiography - Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma | Phase 2 | Recruiting | Northwestern University | 73 | 2024-09-19 | 2026-10-13 |
| Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma Chidamide Tablets combined with AK112 - Sarcoma,Soft Tissue, Sarcoma | Phase 2 | Recruiting | Shanxi Province Cancer Hospital | 30 | 2024-08-01 | 2024-10-15 |
| PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT) - Sarcoma, Sarcoma,Soft Tissue | Phase 2 | Recruiting | Ruijin Hospital | 86 | 2023-06-01 | 2023-10-31 |
| Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors Doxorubicin, Cisplatin, Methotrexate, Doxorubicin, Cisplatin - Osteosarcoma, Neoplasms, Connective Tissue | Phase 2 / Phase 3 | Unknown | Blokhin's Russian Cancer Research Center | 50 | 2022-01-10 | 2024-04-01 |
Osteosarcoma (5) · Sarcoma (4) · Bone Neoplasms (2) · Sarcoma, Ewing (2) · Sarcoma, Synovial (2) · Leiomyosarcoma (1) · Lymphoma (1) · Neoplasms, Connective Tissue (1) · Neoplasms, Connective and Soft Tissue (1) · Sarcoma, Kaposi (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Bone Tissue (5) · Neoplasms, Connective Tissue (4) · Neoplasms, Connective and Soft Tissue (4) · Bone Diseases (2) · Musculoskeletal Diseases (2) · Neoplasms by Site (2) · Connective Tissue Diseases (1) · DNA Virus Infections (1) · Hemic and Lymphatic Diseases (1) · Herpesviridae Infections (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Infections (1)
Cisplatin (1) · Doxorubicin (1) · Methotrexate (1) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (1) · Specimen Handling (1) · camrelizumab (1) · fluzoparib (1)
Blokhin's Russian Cancer Research Center (1) · Essen Biotech (1) · Northwestern University (1) · Ruijin Hospital (1) · Shanxi Province Cancer Hospital (1)
China (3) · Russia (1) · United States (1)
Beniamin Bokhyan, PhD (1) · Junxiang Wen, PhD, MD (1) · Pedro Hermida de Viveiros, MD (1) · Qiyuan Bao, PhD, MD (1) · Weibin Zhang, PhD, MD (1) · Xin Wang (1) · Yuhui Shen, PhD, MD (1)
P30CA060553 (1)